No Data
No Data
Wedbush Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $11
Wedbush analyst Robert Driscoll maintains $Monte Rosa Therapeutics(GLUE.US)$ with a buy rating, and maintains the target price at $11.According to TipRanks data, the analyst has a success rate of 43.8
Express News | Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $11 Price Target
Monte Rosa Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 150.28% Wedbush → $11 Reiterates Outperform → Outperform 02/15/2024 150.28% Wedbush → $11 Initi
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Aerovate Therapeutics (AVTE)
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits colitis disease progression and colon inflammation, lowers inflammatory mucosal cytokines, and reduces expression of IBD-associated genes in a colitis
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index decreasing 0.1% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. The iShares Biotechnology ETF (IBB) wa
No Data